Vitamin D Lessens Symptoms of Severe Eczema in Children
Noviembre 4, 2020
Vitamin D Lessens Symptoms of Severe Eczema in Children
Vitamin D supplementation eased the symptoms experienced by children with severe atopic dermatitis, according to a randomised study published in Pharmacology Research & Perspectives.
"Standard initial treatment modalities for the management of atopic dermatitis are centred around the use of topical steroid preparations and moisturisation of the skin," wrote Noha O. Mansour, MD, Mansoura University, Mansoura, Egypt, and colleagues. "Patients with severe disease who fail to improve with this initial conventional therapy might benefit from second‐line therapies, such as systemic and topical immunosuppressive medications. However, most of these therapies have potential adverse effects and nearly all are off-label for children. The present study was designed to test the hypothesis that vitamin D supplementation as an adjuvant therapy might benefit children with severe atopic dermatitis children. According to our knowledge our study is the first to assess the efficacy of vitamin D in conjunction with standard treatment in patients with severe eczema."
For the study, 86 children and adolescents with severe atopic dermatitis were randomised to receive vitamin D3 1600 IU/day or placebo, plus baseline therapy of topical 1% hydrocortisone cream twice daily for 12 weeks.
The primary endpoints were the change in mean Eczema Area and Severity Index (EASI) score at the end of the study and the mean percent change in EASI score from baseline to week 12.
At baseline, there was no significant difference between the 2 groups in serum level of 25-hydroxycholecalciferol (25[OH]D); however, there was a high prevalence of 25(OH)D deficiency among all patients.
Patients in the vitamin D supplementation group achieved a significant higher level of 25(OH)D compared with the control group at week 12 (P< .001). At the end of the study, the mean percentage change from baseline in EASI score was significantly greater in the vitamin D group (56.44%) than the placebo group (42.09%; P = .039).
Notably, about 38.6% of supplemented patients achieved EASI 75 compared with only 7.1% of patients in the placebo group.
"Our study suggests that oral daily vitamin D supplementation might provide clinical improvement in children with severe atopic dermatitis," the authors wrote. "Further studies are needed to examine whether the positive impact of supplementation would be maintained in winter‐related severe eczema."
Reference: https://bpspubs.onlinelibrary.wiley.com/doi/10.1002/prp2.679
"Standard initial treatment modalities for the management of atopic dermatitis are centred around the use of topical steroid preparations and moisturisation of the skin," wrote Noha O. Mansour, MD, Mansoura University, Mansoura, Egypt, and colleagues. "Patients with severe disease who fail to improve with this initial conventional therapy might benefit from second‐line therapies, such as systemic and topical immunosuppressive medications. However, most of these therapies have potential adverse effects and nearly all are off-label for children. The present study was designed to test the hypothesis that vitamin D supplementation as an adjuvant therapy might benefit children with severe atopic dermatitis children. According to our knowledge our study is the first to assess the efficacy of vitamin D in conjunction with standard treatment in patients with severe eczema."
For the study, 86 children and adolescents with severe atopic dermatitis were randomised to receive vitamin D3 1600 IU/day or placebo, plus baseline therapy of topical 1% hydrocortisone cream twice daily for 12 weeks.
The primary endpoints were the change in mean Eczema Area and Severity Index (EASI) score at the end of the study and the mean percent change in EASI score from baseline to week 12.
At baseline, there was no significant difference between the 2 groups in serum level of 25-hydroxycholecalciferol (25[OH]D); however, there was a high prevalence of 25(OH)D deficiency among all patients.
Patients in the vitamin D supplementation group achieved a significant higher level of 25(OH)D compared with the control group at week 12 (P< .001). At the end of the study, the mean percentage change from baseline in EASI score was significantly greater in the vitamin D group (56.44%) than the placebo group (42.09%; P = .039).
Notably, about 38.6% of supplemented patients achieved EASI 75 compared with only 7.1% of patients in the placebo group.
"Our study suggests that oral daily vitamin D supplementation might provide clinical improvement in children with severe atopic dermatitis," the authors wrote. "Further studies are needed to examine whether the positive impact of supplementation would be maintained in winter‐related severe eczema."
Reference: https://bpspubs.onlinelibrary.wiley.com/doi/10.1002/prp2.679
Sent from my iPhone
Clinica Victoria en San Pedro: 4000-1054
Momentum Escazu: 2101-9574
Please excuse the shortness of this message, as it has been sent from
a mobile device.
Benjamin Hidalgo-Matlock
Skin Care Physicians of Costa Rica
Skin Care Physicians of Costa Rica
Clinica Victoria en San Pedro: 4000-1054
Momentum Escazu: 2101-9574
Please excuse the shortness of this message, as it has been sent from
a mobile device.
posted by dermatica at
November 05, 2020
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home